Skip to Content
 

VICC toll-free number 1-877-936-8422

Clinical Trials for Dexamethasone

12 Open Trials

    Trial Type Protocol No. &
    Open Date
    Summary

    Treatment

    COGADVL1522

    08/02/2016

    A Phase 2 Study of IMGN901 (Lorvotuzumab Mertansine; IND# 126953, NSC# 783609) in Children with Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor (MPNST) and Synovial Sarcoma

    Treatment

    VICCTHO15117

    05/19/2016

    A Phase 2 Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line Treatment of Patients with Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Carcinoma (TRINITY)

    Treatment

    COGAAML1331

    04/28/2016

    A Phase III Study for Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APL) using Arsenic Trioxide and All-Trans Retinoic Acid

    Treatment

    COGAALL1331

    02/01/2016

    Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND# 117467, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)

    Treatment

    VICCHEM15112

    01/11/2016

    A Phase 1/2 Open-label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed/Refractory Multiple Myeloma

    Treatment

    VICCHEM14131

    11/17/2015

    Phase 1b Study of Carfilzomib Administered Once Weekly in Combination with Lenalidomide and Dexamethasone in Subjects with Multiple Myeloma

    Treatment

    VICCHEMP1558

    10/09/2015

    A Phase 1a/1b, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB052793 in Subjects With Advanced Malignancies

    Treatment

    VICCHEM1437

    09/29/2015

    A Randomized Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Years of Age

    Treatment

    COGAALL1231

    05/13/2015

    A Phase III Randomized Trial Investigating Bortezomib NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)

    Treatment

    ECOGTHOS1400

    04/02/2015

    Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer

    Treatment

    COGANHL12P1

    10/20/2014

    A Randomized Phase II Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC#749005, commercially labeled) in Combination with Chemotherapy for Newly Diagnosed Patients with Anaplastic Large Cell Lymphoma (ALCL) IND # 117117

    Treatment

    VICCHEM1146

    08/14/2012

    Ofatumumab in Combination with High Dose Cytarabine Chemoimmunotherapy for Patients with Newly Diagnosed Mantle Cell Lyjmphoma


    Print this page for your doctor